US says that it will review Moderna flu vaccine it previously declined | Health News
The pharmaceutical giant expressed optimism that its new flu shot would be available this year, after approval concerns. Listen to this article | 3 mins info By Reuters and The Associated Press Published On 18 Feb 202618 Feb 2026 Click here to share on social media share2 Share The federal agency tasked with regulating drugs in the United States has said it will review a flu vaccine application from the pharmaceutical giant Moderna, one week after it declined to do so in an unusual move. Moderna announced on Wednesday that the Food and Drug Administration (FDA) had accepted a revised application seeking full approval for a new flu shot to be offered to patients between the ages of 50 and 64 and expedited approval for those over 65. Recommended Stories list of 3 itemsend of list “Pending FDA approval, we look forward to making our flu vaccine available later this year so that America’s seniors have access to a new option to protect themselves against flu,” CEO Stephane Bancel said in a statement. He also expressed thanks …








